Hamlet Pharma has participated in a number of recent events, presenting highligts from the promising clinical studies and our future strategy. With this newsletter, we would like to invite you to see these presentations, using the links below.
Hamlet Pharma’s drug candidate Alpha1H has shown great promise as a cancer treatment in animal models and in clinical studies. We have chosen bladder cancer as the first clinical indication. Bladder cancers are extremely common and difficult to treat. The a lack of new therapies makes bladder cancer one of the most expensive cancer forms and the FDA has identified bladder cancer as a “great unmet medical need”.
Hamlet Pharma’s strategy is to bring Alpha1H to the market primarily for patients suffering from bladder cancer. The controlled clinical trial program shows excellent effects that increase with the dose of Alpha1H. The strong IP position together with proven safety and efficacy in clinical studies provides an excellent basis for developing Alpha1H for other cancer indications as well.
We have recently presented the latest clinical results and development strategies at several events.
Please click on the links below to take part in our exciting journey towards new tretments for cancer patients.
Stockholm Corporate Finance Life Science Days event, March 8, 2022. (Swedish)
Interview with Catharina Svanborg and Mats Persson, Stockholm Corporate Finance Life Science Days event, March 8, 2022 (Swedish)
Naventus Healthcare Summit, Stockholm May 10, 2022 (English)
3rd International Donor Milk Research Congress, Milano, Italy, May 13, 2022 (English) The HAMLET story – from the lab to clinical trials
The link will be available on https://hamletpharma.com next week
Microsoft Word – Hamlet Pharma_Newsletter_Communication 18 maj 2022_final.doc
For more information, please contact
Catharina Svanborg, Chairman and founder of Hamlet Pharma, +46-709 42 65 49
Mats Persson, CEO of Hamlet Pharma, +46-70517 6757
About HAMLET Pharma
HAMLET Pharma, listed on Spotlight, develops drugs based on the unique tumoricidal protein-lipid complex, HAMLET, formed by two natural and harmless molecules found in human milk. Development focuses primarily on drugs, for the treatment and prevention of cancer. HAMLET kills tumour cells and has proven safe in proof-of-concept studies in animal models. Alpha1H is the synthetic variant of HAMLET, which has enabled development of the agent for clinical trials. Alpha1H kills different types of tumour cells and has demonstrated therapeutic effects against bladder cancer in animal models. In an ongoing clinical trial with Alpha1H in patients with bladder cancer, potent tumor responses have been demonstrated compared to patients who received placebo. The results from the ongoing clinical study show no drug-related side effects of Alpha1H, indicating that the treatment is safe and well tolerated. Bladder cancer is a common and costly form of cancer that is difficult to treat and has been declared an unmet medical need. HAMLET Pharma is further expanding its activities into other cancer indications. In addition, Hamlet Pharma has initiated the drug development phase of BAMLET; a molecular complex of bovine α-lactalbumin and oleic acid. Data from animal models show that local BAMLET treatment may be effective against cancers such as colon cancer.